Last reviewed · How we verify
Tobramycin + Dexamethasone — Competitive Intelligence Brief
marketed
Antibiotic + corticosteroid combination
Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)
Ophthalmology / Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Tobramycin + Dexamethasone (Tobramycin + Dexamethasone) — Umm Al-Qura University. Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tobramycin + Dexamethasone TARGET | Tobramycin + Dexamethasone | Umm Al-Qura University | marketed | Antibiotic + corticosteroid combination | Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone) | |
| Antibiotics + Corticosteroids | Antibiotics + Corticosteroids | George Washington University | marketed | Antibiotic + Corticosteroid combination | ||
| moxifloxacin / dexamethasone | moxifloxacin / dexamethasone | Federal University of São Paulo | marketed | Fluoroquinolone antibiotic + corticosteroid combination | Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor | |
| Ciprofloxacin HCl and Hydrocortisone | Ciprofloxacin HCl and Hydrocortisone | Farmoquimica S.A. | phase 3 | Fluoroquinolone antibiotic + corticosteroid combination | Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor | |
| Moxifloxacin / Dexamethasone Ophthalmic Solution | Moxifloxacin / Dexamethasone Ophthalmic Solution | Laboratorios Sophia S.A de C.V. | phase 3 | Fluoroquinolone antibiotic + Corticosteroid combination | Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone) | |
| Levofloxacin + dexamethasone followed by dexamethasone | Levofloxacin + dexamethasone followed by dexamethasone | NTC srl | phase 3 | Fluoroquinolone antibiotic + corticosteroid combination | Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone) | |
| Clindamycin+Dexamethasone | Clindamycin+Dexamethasone | Shahid Beheshti University of Medical Sciences | phase 3 | Antibiotic + Corticosteroid combination | Bacterial 50S ribosome (clindamycin); Glucocorticoid receptor (dexamethasone) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antibiotic + corticosteroid combination class)
- Umm Al-Qura University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tobramycin + Dexamethasone CI watch — RSS
- Tobramycin + Dexamethasone CI watch — Atom
- Tobramycin + Dexamethasone CI watch — JSON
- Tobramycin + Dexamethasone alone — RSS
- Whole Antibiotic + corticosteroid combination class — RSS
Cite this brief
Drug Landscape (2026). Tobramycin + Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/tobramycin-dexamethasone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing